Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02673749 · ClinicalTrials.gov registry record · Phase 2

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

A Phase 2 study, sponsored by Ritter Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
377
Enrollment target

NCT02673749 is a Phase 2 study that has completed, run by Ritter Pharmaceuticals. The registered enrollment target is 377 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02673749, a Phase 2 study, has completed, sponsored by Ritter Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
377 participants
Enrollment target

Study Summary

RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).

Interventions

  • OTHER Placebo
  • DRUG RP-G28

Trial Details

FieldValue
Enrollment Target 377 participants
Start Date 2016-02
Est. Completion 2016-10
Phase Phase 2

Sponsor

Ritter Pharmaceuticals

4 total trials

What the Registry Record Tells You About NCT02673749

The ClinicalTrials.gov registry entry for NCT02673749 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ritter Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02673749 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02673749 about?

NCT02673749 is a clinical study titled "Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance". RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).

What is the current status of trial NCT02673749?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 377 participants. The study started on 2016-02. Estimated completion is 2016-10.

What interventions are being tested in trial NCT02673749?

The interventions under investigation include: Placebo (OTHER), RP-G28 (DRUG).

Who is sponsoring clinical trial NCT02673749?

This trial is sponsored by Ritter Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.